Oricell advanced its GPC3-directed strategy in liver cancer, moving its autologous CAR T therapy Ori-C101 into a confirmatory registration Phase 2 trial in patients with GPC3-positive advanced hepatocellular carcinoma. The company positions the program as the first GPC3 immune cell therapy reaching that stage and, as described, the first CAR T dedicated to liver cancer to enter this phase. If confirmatory data translate to durable responses in the target population, Ori-C101 could reshape how CAR T is prioritized for solid tumors where hepatic delivery and persistence remain key hurdles.